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Abstract: To date, 5-Fluorouracil (5FU) is a major component of several chemotherapy regimens,
thus its study is of fundamental importance to better understand all the causes that may lead to
chemoresistance and treatment failure. Given the evident differences between prognosis in Asian
and Caucasian populations, triggered by clear genetic discordances and given the extreme genetic
heterogeneity of gastric cancer (GC), the evaluation of the most frequent mutations in every single
member of the 5FU conversion and activation pathway might reveal several important results. Here,
we exploited the cBioPortal analysis software to query a large databank of clinical and wide-genome
studies to evaluate the components of the three major 5FU transformation pathways. We demonstrated
that mutations in such ways were associated with a poor prognosis and reduced overall survival,
often caused by a deletion in the TYMP gene and amplification in TYMS. The use of prodrugs and
dihydropyrimidine dehydrogenase (DPD) inhibitors, which normally catabolizes 5FU into inactive
metabolites, improved such chemotherapies, but several steps forward still need to be taken to
select better therapies to target the chemoresistant pools of cells with high anaplastic features and
genomic instability.
Keywords: 5 fluorouracil; chemoresistance; gastric cancer; mutations
1. Introduction
The drug 5-fluorouracil (5FU) is one of the most commonly used drugs to treat several kinds of
tumors, including breast cancer, head and neck cancers, gastric cancer, colon cancer, and melanoma [1].
Discovered for the first time in 1957 by Charles Heidelberger and colleagues at the University of
Wisconsin [2], it has become a major therapeutic option when specific targets are not available and
when surgery is not practicable. Indeed, 5FU is actively absorbed by highly proliferating tissues,
especially tumor ones, that need uracil for nucleic acid biosynthesis, and thus acts by inhibiting
tumor cell division exploiting two different ways: it may inhibit the thymidylate synthase (TYMS),
forming a covalent ternary complex with 5,10-methylenetetrahydrofolate, suppressing in that way
the DNA synthesis, or it might be incorporated into RNA molecules blocking gene expression [3].
Once internalized into tumor cells, 5FU is converted to fluorouridine monophosphate (FUMP) by the
orotate phosphoribosyltransferase (OPRT) and then converted to fluorodeoxyuridine monophosphate
(FdUMP) by the ribosyl reductase complexes (RRM1/2), a biochemical process better known as the
“OPRT–RR pathway” [4]. While FdUMP inhibits DNA synthesis through its inhibitory action on
Biology 2020, 9, 265; doi:10.3390/biology9090265 www.mdpi.com/journal/biology
Biology 2020, 9, 265 2 of 16
TYMS, FUMP is largely responsible for the inhibition of gene expression through its incorporation
into mRNAs. Another conversion way is mediated by the action of the thymidine phosphorylase
(TYMP), which is able to convert 5FU into fluorodeoxyuridine (FdU) and then transformed to FdUMP
due to the action of the thymidine kinase 1 (TK1), in a process called “TP–TK pathway”. FdUMP
might also be converted back to FdU by the nucleotidase NT5E [5]. Moreover, uridine monophosphate
synthase (UMPS) and phosphoribosyl pyrophosphate amidotransferase (PPAT) are also responsible
for the conversion of 5FU to FUMP, which is in turn processed to fluorouridine diphosphate (FUDP)
and then to FdUMP by RRM1 and 2 [6,7]. FUMP reservoir can be fueled also by the transformation of
fluorouridine (FUR) triggered by uridine kinase (UK), generated in turn by the conversion of 5FU by
the uridine phosphorylase (UP). All these steps are summarized in the schematic view in Figure 1.
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doxifluridine) [11–13] and DPD inhibitors (gimeracil, uracil, eniluracil, 5-chloro-2,4-
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gastric cancer (GC), together with bladder, lung and melanoma, is one tumor histotype with the 
highest mutation frequency [17]. GC is to date the fifth most frequently diagnosed cancer and the 
third leading cause of cancer death according to GLOBOCAN 2018 [18], and due to the lack of 
macroscopical manifestations in the early phases of the disease, it is often diagnosed only after 
metastasis in advanced stages, when surgery is not practicable and the only therapeutic option is 
chemotherapy. According to the international guidelines, the first-line approach for therapy would 
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Figure 1. A simplified diagram of the 5-fluorouracil (5FU) conversion system. Uridine phosphorylase
(UP), uridine kinase (UK), fluorouridine (FUR), orotate phosphoribosyltransferase (OPRT), fluorouridine
monophosphate (FUMP), ribosyl reductase complexes (RRM1/2), fluorodeoxyuridine monophosphate
(FdUMP), thymidylate synthase (TYMS), thymidine phosphorylase (TYMP), fluorodeoxyuridine
(FdU), thymidine kinase 1 (TK1), nucleotidase (NT5E), uridine monophosphate synthase (UMPS),
phosphoribosyl pyrophosphate amidotransferase (PPAT), and fluorouridine diphosphate (FUDP).
In order to study che oresistance and its side-effects, it is important to remark the action
of the dihydropyrimidine dehydrogenase (DPD), which catabolizes 5FU into in ctiv metabolites
by the liver [8], producing fluoro cetate and fluorohydroxypropionic cid, which have been
reported to in uce ardiotoxicity and neurotoxicity [9,10]. While 5FU is normally administered
intravenously to avoid the DPD digestion by the gut wall, the use of oral 5FU prodrugs
(capecitabine, tegafur, and doxifluridine) [11–13] and DPD inhibitors (gimeracil, uracil, eniluracil,
5-chloro-2,4-dihydroxypyridine) [14–16] partially resolves the above-described side-effects. Every
single mutation in one of the above-described enzymes might affect irreversibly the sensitivity to 5FU
leading to the generation of subpopulations of chemoresistant cancer cells, which cause therapy failure.
Indeed, gastric cancer (GC), together with bladder, lung and melanoma, is one tumor histotype with the
highest mut tion frequency [17]. GC is to date the fifth most frequently diagnosed cancer and the third
leading ause of cancer death according to GLOBOCAN 2018 [18], and due to the lack of macroscopical
manifestations i the early phases of the disease, it is often diagnose only after metastasis in advanced
stages, when surgery is not practicable and the only therapeutic option is chemotherapy. According to
the international guidelines, the first-line approach for therapy would involve treating HER2 negative
patients with platinum-based drugs (cisplatin or oxaliplatin) and fluoropyrimidines (5-fluorouracil or
capecitabine) otherwise, trastuzumab is added to treat HER2 positive patients. In Eastern countries,
S-1 (tegafur-gimestat-otastat potassium), an oral fluoropyrimidine regimen, is commonly used [19].
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The addition of taxanes to first-line chemotherapy, as in DCF (docetaxel, cisplatin, and 5-fluorouracil)
or FLOT (5-fluorouracil, oxaliplatin, and docetaxel) is normally exploited only for young patients with
good performance due to high toxicity effects [20,21]. To date, the second-line regimens are composed
of ramucirumab alone or in combination with paclitaxel [22,23] or 5FU and irinotecan (FOLFIRI) [24]
when patients are not responsive to the first ones. The vast majority of GC are adenocarcinomas,
which can be classified mainly by two different approaches: the Lauren histopathology system, which
distinguishes the intestinal, the diffuse and the mixed subtypes based on immunohistochemical
analysis, and the Cancer Genome Atlas (TCGA) research network-derived classification, based on
in situ hybridization techniques dividing GC into four subgroups, i.e., Epstein–Barr virus-positive,
microsatellite unstable, genomically stable, and chromosomally unstable GCs [25,26]. In this context,
another molecular classification called “Singapore–Duke” was recently reported [27]. Such a study
analyzed the gene expression profiles of 248 gastric tumors, identifying three different subtypes
(proliferative, metabolic, and mesenchymal) [21]. The proliferative subtype was characterized by high
expression of E2F, MYC, RAS, cell cycle genes and frequent TP53 mutation, copy number amplification,
DNA hypomethylation, and a Lauren intestinal type, while the metabolic was reported to gain an
upregulation of metabolic and digestion-related genes that are normally expressed in gastric mucosa,
elevated expression of cell adhesion proteins, extracellular matrix (ECM) receptors, and the activation of
EMT and cancer stem cell pathways. The mesenchymal subtype was instead associated with a Lauren
diffuse type, characterized by alterations in TP53, transforming growth factor β (TGFβ), vascular
endothelial growth factor (VEGF), NF-κB, mTOR, and Shh signaling pathways. It is relevant to report
that the Singapore–Duke study evidenced that the metabolic subtype was more sensitive to 5FU than
the others, including metabolic GC patients that showed greater responsiveness to 5FU chemotherapy.
Such higher sensitivity could depend on the reported lower expression of TYMS and DPD proteins in
the metabolic GCs; however, the three subtypes showed no significant differences in cancer-specific
and disease-free survival. Indeed, the new molecular classifications were introduced due to the
extreme genetic heterogeneity of GC that has also been observed in studies on somatic copy number
alterations, gene mutations, and epigenetic and transcriptional changes [28]. Moreover, in accordance
with the elevated genetic instability, mutations found in GCs are extremely divergent and, actually,
no characteristic driver gene mutations have been identified. Here, we focused on the most recurrent
gene mutations in cancer, i.e., amplification, missense, and truncating mutations, frameshift effects,
and oncogenes fusion. We analyzed the major steps in 5FU conversion, evaluating and discussing
where worldwide research need to focus the attention for future therapies. Our manuscript aims to
focus the attention of the scientific community on the research of reliable markers, which might reflect
the chemosensitivity status of the patients and may be evaluable in course of therapy.
2. Materials and Methods
2.1. Analysis of Genomic Data
The cBioPortal for Cancer Genomics [29] was used to explore, visualize, and analyze cancer
genomics data from human cancer tissues and cell lines. The database was queried for UPP1, UCK1,
UMPS, RRM1/2, TYMP, TYMS, TK1, NT5E, and PPAT, and the conditions for the analysis visualization
were adjusted as reported in each legend. The genomic data types evaluated include genomic
mutations, somatic mutations, and DNA copy-number alterations (CNAs). The effect of target genes
mutation on the prognosis of GC was evaluated by a Kaplan–Meier plotter, generated by cBioPortal
tool (https://www.cbioportal.org/).
2.2. Protein–Protein Interaction Analysis
STRING v11 was used to generate and visualize a complex map of all the known and predicted
interactions among the queried proteins setting 0.400 as the minimum required confidence for the
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interaction score [30]. The proteins involved in angiogenesis were selected from the most recent topic
publications available in the literature.
2.3. TYMP Expression Analysis
The expression level of TYMP in GC vs. normal tissues was analyzed through the “cancer vs.
normal” filter in the Oncomine database selecting all GC studies available [31,32]. All data conforming
to the criteria of p < 0.05, fold-change > 2, and a gene rank percentile <10% were included in the
present study [33].
2.4. Statistical Analysis
Survival curves and graphs were plotted using cBioPortal, displayed with p values calculated by
long-rank test. The statistical analysis of the data retrieved from Oncomine was calculated by t-test.
All values were corrected on the false discovery rate.
3. Results
3.1. 5FU System Mutations Lead to a Poor Prognosis
As 5FU is one of the most diffuse components of chemotherapy regimens in many kinds of cancers,
we decided to exploit the cBioPortal analysis software and database to better understand the impact of
mutations in any of the enzymes that belong to such a pathway. We identified 10 genes, as reported
in the Material and Methods Section, involved in 5FU conversion, and we selected two cohorts: one
comprising all patients with at least one of the selected genes mutated (the altered group) and one
including all with “unaltered” genes. Evaluating all kind of mutations in a broad range of cancer
studies (32 studies including 10953 patients, TCGA PanCancer Atlas), we observed significant changes
in the overall survival (OS) curve, with a reduction of the median OS time from 80.74 months of the
unaltered group to 67.46 months of the altered one (Table 1), as shown in the Kaplan–Meier plots
in Figure 2. We also evidenced a lower median for disease-free (DF), progression-free (PFS), and
disease-specific survival (DSS) in the altered cohort. Such indexes were calculated as the disease-free
status since the initial treatment, the chance of staying free of disease progression after treatment, and
the percentage of patients who have not died starting at the time of diagnosis or at the start of treatment,
respectively. In Table 1, we indicated the percentage and the median of such indexes. It is important to
remark that we were unable to calculate the median month DF as the curves did not interpolate the
50% of the y-axis, but nonetheless, the difference between the two groups was statistically significant
(p = 0.0114). Using an alternative analysis strategy, we also compared the unaltered cohort to the
singular mutation genes groups evidencing that while mutations in RRM1 might have a positive
impact on the OS, mutations in UPP1 are strongly associated with a worse prognosis (Supplementary
Figure S1 and Supplementary Table S1). Larger studies comprising not only the mutational profile but
also a proteomic analysis will better clarify the real impact of such mutations in cancer progression.
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3.2. 5FU Conversion System utation Frequency among Cancers
To better understand the relevance of 5FU conversion system mutations in cancers, we analyzed
the frequency of the 10 queried genes in several types of cancers, taking into consideration all kinds of
possible mutations. Globally, such genes were found to be altered in a total of 1488 (14%) of queried
samples/patients, including a total of 639 different genetic alterations. As shown in Figure 3, the three
most frequently mutated histotypes of cancers are the ovarian, the endometrial, and the bladder
urothelial carcinoma, while esophagogastric cancers are only ninth in such classifications. hile the
proportions among the several kinds of mutations are almost constant, it is evident that for ovarian
cancer and prostate adenocarcinoma deep deletions account for about half of the analyzed utations.
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Figure 3. Global analysis of the cumulative alteration frequency of the queried genes per cancer type
revealed that ovarian, endometrial, and bladder urothelial carcinomas are the three types of cancer with
the higher frequency of mutation in the 5FU conversion system; only cases with >5% changes, occurring
in a minimum of 100 total cases are represented; CNA, copy number alteration. Data retrieved from 32
studies including 10953 patients, TCGA PanCancer Atlas.
3.3. Individual Analysis of Mutation Frequency
More than a global analysis, the queried genes were analyzed also for mutation frequency
singularly. As shown in Figure 4, TYMP had the highest percentage of mutation, especially in ovarian
epithelial cancer, while UCK1, which is frequently mutated in endometrial carcinoma, is the less
present among the screened genes. Indeed, UCK1 is not often observed mutated and, as already
evaluated by Murata and colleagues, its level did not change even in a chemoresistant model of human
fibrosarcoma and gastric carcinoma [34]. It is interesting to notice that the vast majority of mutations
for TYMP are classified as deep deletions, while for TYMS they are amplifications. These phenomena
could be in line with the fact that TYMP is responsible for the conversion of 5FU into its active form,
while TYMS is its final target, responsible for the conversion of deoxyuridine monophosphate (dUMP)
to deoxythymidine monophosphate (dTMP), an important step to fuel the pool of DNA precursor for
replication. Thus, when TYMP is deleted 5FU could only be activated by the other two pathways
(see Introduction) leading to worse chemotherapy response and to the increase of the concentration of
inactive 5FU [35] causing cytotoxic side-effects, while amplification of TYMS makes harder for 5FU to
exert its action [36].
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3.4. 5FU Conversion System Mutations Analysis in GC
As reported by Lawrence et al. [17], gastrointestinal tumors demonstrated an extremely high
frequency of transition mutations at CpG dinucleotides, and also Tan et al. [28] stated that GCs are often
characterized by several somatically acquired mutations in various genes, estimating approximately
50 to 70 nonsynonymous mutations, a mutation level comparable to colon and esophageal cancers.
Indeed, while previously GC was believed to rely on mutations induced only by environmental factors
(food and alcohol habits, smoke, BMI, and Helicobacter pylori), recently it was better understood
the predominant role of the genetic compartment, as demonstrated by the genetic and molecular
discordances between different race/ethnicities [37] or sex (i.e., the signet cell ring carcinoma—[38]).
Moreover, to date, being well-known the discordances between Asian and Caucasian populations’
prognosis in GC [37,39], it is now clear that the genetic component exerts a fundamental action
especially in this kind of cancer. To better understand the role of the 5FU conversion system mutations
in GC, we analyzed all the above-described genes focusing on the mutations presented only in GC
studies [26,29,40–48]. As shown in Table 2, the most frequently mutated genes were TYMP, NT5E, UPP1,
and UCK1, whereas globally the missense mutations were predominant with respect to the truncating
ones, while inframe mutations were reported only in NT5E. We also reported in the Supplementary
Table S2, the number of cases of co-occurrence of 5FU-related mutations, highlighting that most patients
in our study suffered from only one mutation at a time among the queried ones.
Table 2. We analyzed the main components of the 5FU conversion system, among 6 studies comprising
1365 patients regarding GC; SMF: somatic mutation frequency.
Gene Protein MutationFrequency
#
Mutations Missense Truncating Inframe SMF
UPP1 Uridinephosphorylase 1 2.6% (35) 3 2 1 0 0.4%





1.4% (18) 6 2 4 0 1.0%
RRM1 Ribonucleotidereductase 1 1.4% (18) 5 5 0 0 1.1%
RRM2 Ribonucleotidereductase 2 1.4% (18) 5 4 1 0 0.8%
TYMP Thymidinephosphorylase 2.8% (37) 4 4 0 0 0.7%
TYMS Thymidylate synthase 1.4% (18) 1 1 0 0 0.2%
TK1 Thymidine kinase 1 1.4% (18) 1 1 0 0 0.1%





2.2% (29) 7 5 2 0 1.3%
N = 46 34 (73.9%) 11 (23.9%) 1 (2.2%)
* OPRT catalytic domain is codified by UMPS; #: Number.
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3.5. The Paradoxical TYMP Expression in GC
It is well-known that TYMP plays a fundamental role in the transformation of 5FU to its active
compound form, and we reported to have the highest mutation frequency (2.8%), accounting for four
different missense mutations, as shown in Figure 5.
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As reported above, TYMP is often deleted in many kinds of cancers but not in GC. Indeed, even
though the loss of TYMP expression leads to an unsuccessful 5FU conversion, causing inevitably
the treatment failure and severe cytotoxic effects due to its accumulation, its expression was found
to be significantly higher in GC tumor tissues, creating a paradox. We decided to examine two
studies reporting TYMP expression comparing GC to the normal gastric epithelia through Oncomine
software [31,32]. As shown in Figure 6, TYMP expression is low in the gastric epithelial mucosa,
while it is upregulated in all the different GCs.
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Such a phenomenon was also reported by Kimura et al. who described TYMP as a powerful prognostic
tool [49]. Indeed, evaluating TYMP expression through the ELISA (enzyme-linked immunosorbent
assay) technique, they examined 263 samples from patients who underwent gastrectomy and identified
a correlation between TYMP and the metastatic process, reporting a high TYMP expression in the
tumor-invading serosa and tumor tissues from patients with lymph node metastasis and lymphatic
invasion. Moreover, Tabata et al. reported that TYMP expression is higher in tumor tissues than in adjacent
non-neoplastic ones in several kinds of cancers. They also correlated its expression with poor prognosis in
colon and differentiated gastric carcinomas, and they demonstrated that thymidine can also serve as a
substrate for the glycolytic pathway in human cancer cells [50]. We do believe that future data about
5FU chemoresistant patients might improve our knowledge about TYMP as a prognostic marker.
3.6. 5FU Conversion System Is Associated with Tumor Angiogenesis
Each member of the 5FU conversion system plays a specific role in the activation of the
chemotherapeutic agent, but such a mechanism is not exclusively associated with the pyrimidine
metabolism. Indeed, the proteins codified by the genes examined in this article are closely associated
with angiogenesis. As shown in the map in Figure 7A, we identified several interactions among 5FU
converting pathway enzymes and some proteins that are frequently associated with the angiogenesis
biological process. Most of the connections were linked through NT5E, which has already been
described as a master angiogenesis regulator [51], and also TYMP plays a fundamental role, interacting
with PECAM1, KDR, FGF2, VEGFA, and ANGPT2. Even though they interact actively, their expression
is not always correlated in GC. Exploiting cBioPortal analysis software, we reported the mutation
frequency of the above-described genes in the altered and unaltered cohorts, comprising 211 and
1154 patients, respectively. As shown in Figure 7B, only ITGB1, ITGA5, PDGFRB, KDR, ANGPT1/2,
and Notch1 were found to be mutated more frequently in association with the alterations of the 5FU
converting system. We also revealed that mutations in the 5FU conversion system are correlated with a
higher mutation frequency of KLF5, Ki67, and CAIX, which are typical progression-associated markers
in GC, as shown in Supplementary Figure S2.
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(B) The analysis of the frequency of the mutations of the genes involved in angiogenesis in the altered
and unaltered group described above. Briefly, the altered one includes all the patients with at least one
of the 5FU metabolic genes mutated and the other one including all the “unaltered”. VEGFA was not
reported in the cBioPortal database analyzi g GC studies only; * p < 0.05.
4. Discussion
5FU is a major component of several chemotherapy regimens, exploited to treat a multitude
of different cancers. Even though 5FU use ad improved in a significant way, the patients’ OS, its
cytotoxic effects as well as the high probability to gain chemoresistance make it necessary to study
further its metabolic and catabolic pathway. We analyzed, exploiting several bioinformatic tools,
the impact and the frequency of mutations in each pathway of the 5FU metabolic biological processes.
We demonstrated that such mutations were associated with a poor prognosis, with a reduced OS, DF,
PFS, and DSS. For this reason, we do believe that such alterations should be constantly evaluated in
patients, especially exploiting the so-called “liquid biopsy” [52]. Indeed, once patients underwent
surgery, oncologists are guided by the Lauren a d the TCGA classifications, but during the thera y, there
are not available opt ons t gai useful informati n about the disease st tu nd to m nit r he success
of the treatment. Therefore, t combinati n of new p l of cancer progression-associated markers
and the liquid biopsy might improve the knowledge of the tumor characteristics and composition,
gaining crucial data about the chemosensitivity status of patients, supporting in such a way the best
choice of treatment. We also identified the ovarian, endometrial, and bladder urothelial carcinomas as
the cancers histotype with the highest mutation frequency, while esophagogastric cancers account for
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more than 15% of mutation frequency, almost equally divided by missense, deletion, and amplification.
Among them, we reported TYMP to be often deleted in several kinds of cancers but not in GC, while
TYMS is frequently amplified, which may lead to treatment failure [35,36]. However, more data are
needed to better understand their roles: as reported, the deep deletion is the most common TYMP
mutation among cancers, leading to a complete loss of expression, while in GC we reported four
missense mutations. Therefore, such deletion of TYMP results in a rare event in GC and needs to be
verified on more samples, as its expression is reported to be increased in both diffuse and intestinal
gastric carcinoma compared to the epithelial mucosa. Moreover, TYMP is commonly reported to
be associated with the metastatic phenotype [49], but no statistical relevant data are available about
its expression in chemoresistant patients. To date, data from literature are only based on in vitro
experimentations on cell lines chronically exposed to 5FU, but the evaluation of tissue samples from
patients is needed to further examine this phenomenon [53]. In contrast with the reported expression
data, Kawahara et al. described TYMP only in tumor-associated macrophages and not in GC cells
but limiting the study only to Asian- and African-derived GC cell lines [54]. Such TYMP-positive
macrophages were demonstrated to promote angiogenesis and metastasis in GC. Its association with
the most commonly reported angiogenic proteins is another point that will be faced with additional
experimental tools. Indeed, we verified that in particular TYMP and the Ecto-5′-nucleotidase NT5E
constitute crossing points with angiogenesis and thus their unbalanced expression in GC may lead to an
improved tumor vascular formation or to the stimulation of the vasculogenic mimicry process [55–57].
Such unbalanced expression in GC, altering the angiogenic vessel network and triggering a vascular
mimicry response, might be one possible phenotype of the chemoresistant pool of cells that often
leads to treatment failure [58]. It is interesting to mention the mitochondrial neurogastrointestinal
encephalomyopathy (MNGIE), which is a rare multisystemic autosomal recessive disorder caused by
TYMP mutations [59]. Such mutations generate a severe thymidine phosphorylase deficiency leading to
ptosis, progressive ophthalmoplegia, gastrointestinal dysmotility, cachexia, peripheral neuropathy, and
leukoencephalopathy. The MNGIE has a higher frequency in European countries with typical mutation
profiles, which might be family inherited and may hide a possible relationship with cancer. We need to
point out that our analysis is limited due to the lack of information about the race/ethnicity, which may
influence gene expression and mutations pattern [37]. Finally, we can affirm that the understanding of
the molecular mechanisms regulating 5FU activation and the consequences of its chronic use will need
to be further evaluated by analyzing biopsy samples and by generating chemoresistant cells, taking
into consideration all the possible variables, such as race/ethnicity and sex.
5. Conclusions
Due to the lack of useful prognostic powerful tools, the selection of efficient chemotherapies
is a hard journey for clinicians. When a patient underwent gastrectomy, the Lauren and the TGCA
classifications describe only how to stratify such tumor masses but rarely give information on which
way needs to be walked to achieve a successful treatment. HER2 evaluation might shed light on the use
of Trastuzumab, but few other options are currently available as “targeted” therapies. We do believe
that the evaluation of TYMP, as the key enzyme of the 5FU pathway, and being the one which is often
find mutated in GC might improve the choice for the best therapy regimen. Indeed, the use of a wrong
treatment not only causes cytotoxicity without any beneficial effects but might also select a pool of
chemoresistant cells that, stimulating tumor angiogenesis, may gain a selective advantage to access
blood and lymphatic vessels to metastasize by stimulating tumor angiogenesis.
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-7737/9/9/265/s1,
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of mutation; Figure S2: GC progression and inflammation markers mutation frequency.
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